keyword
MENU ▼
Read by QxMD icon Read
search

RAI refractory thyroid cancer

keyword
https://www.readbyqxmd.com/read/27837029/digitalis-like-compounds-facilitate-non-medullary-thyroid-cancer-redifferentiation-through-intracellular-ca2-fos-and-autophagy-dependent-pathways
#1
Marika H Tesselaar, Thomas Crezee, Herman G Swarts, Danny Gerrits, Otto C Boerman, Jan B Koenderink, Hendrik G Stunnenberg, Mihai G Netea, Jan Wa Smit, Romana T Netea-Maier, Theo S Plantinga
Up to 20-30% of patients with metastatic non-medullary thyroid cancer have persistent or recurrent disease resulting from tumour dedifferentiation. Tumour redifferentiation to restore sensitivity to radioactive iodide (RAI) therapy is considered a promising strategy to overcome RAI resistance. Autophagy has emerged as an important mechanism in cancer dedifferentiation. Here, we demonstrate the therapeutic potential of autophagy activators for redifferentiation of thyroid cancer cell lines. Five autophagy activating compounds, all known as digitalis-like compounds, restored hNIS expression and iodide uptake in TC cell lines...
November 11, 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27734713/lenvatinib-for-the-treatment-of-radioiodine-refractory-differentiated-thyroid-carcinoma-a-systematic-review-and-indirect-comparison-with-sorafenib
#2
Pawel Kawalec, Iwona Malinowska-Lipień, Tomasz Brzostek, Maria Kózka
Thyroid carcinoma is the most prevalent endocrine malignancy, with an increasing incidence over the past decades. Treatment of differentiated thyroid cancer consists of surgery followed by radioactive iodine (RAI) ablation of the thyroid remnant, and TSH suppression. Among new therapeutic solutions for patients with advanced RR-DTC stage, the most promising seem to be sorafenib and lenvatinib, up to now considered to be orphan drugs. Areas covered: We performed a systematic review of medical databases to collect all eligible clinical trials referring to the topic of our analysis...
October 28, 2016: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/27704399/consensus-on-the-management-of-advanced-radioactive-iodine-refractory-differentiated-thyroid-cancer-on-behalf-of-the-spanish-society-of-endocrinology-thyroid-cancer-working-group-gtseen-and-spanish-rare-cancer-working-group-gethi
#3
J Capdevila, J C Galofré, E Grande, C Zafón Llopis, T Ramón Y Cajal Asensio, E Navarro González, P Jiménez-Fonseca, J Santamaría Sandi, J M Gómez Sáez, G Riesco Eizaguirre
Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppressive therapy achieve an overall survival (OS) rate of 97.7 % at 5 years. Nevertheless, locoregional recurrence occurs in up to 20 % and distant metastases in approximately 10 % at 10 years. Two-thirds of these patients will never be cured with radioactive iodine therapy and will become RAI-refractory, with a 3-year OS rate of less than 50 %...
October 4, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27618325/current-concepts-in-the-molecular-genetics-and-management-of-thyroid-cancer-an-update-for-radiologists
#4
Tatiana Kelil, Abhishek R Keraliya, Stephanie A Howard, Katherine M Krajewski, Marta Braschi-Amirfarzan, Jason L Hornick, Nikhil H Ramaiya, Sree Harsha Tirumani
Substantial improvement in the understanding of the oncogenic pathways in thyroid cancer has led to identification of specific molecular alterations, including mutations of BRAF and RET in papillary thyroid cancer, mutation of RAS and rearrangement of PPARG in follicular thyroid cancer, mutation of RET in medullary thyroid cancer, and mutations of TP53 and in the phosphatidylinositol 3'-kinase (PI3K)/AKT1 pathway in anaplastic thyroid cancer. Ultrasonography (US) and US-guided biopsy remain cornerstones in the initial workup of thyroid cancer...
September 2016: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/27614988/multitargeted-kinase-inhibition-in-metastatic-differentiated-radioiodine-refractory-thyroid-cancer-a-look-at-new-therapeutic-options-for-a-rare-disease
#5
Katharina Mischler, Stefan Kneifel, Richard Cathomas
BACKGROUND: Metastatic differentiated thyroid cancer (DTC) is a rare disease that is in the first line treated with iodine-131 radioisotope therapy. Until recently, options were very limited in the case of progressive radioactive-iodine (RAI)-refractory disease. Based on new study results, tyrosine kinase inhibitors (TKIs) have attracted attention. The TKI sorafenib demonstrated significantly improved progression-free survival (PFS) in a phase III trial. Recent data from another phase III trial showed that the TKI lenvatinib achieved high response rates and a large improvement in PFS in metastatic RAI-refractory DTC patients in the first-line setting and after 1 prior line of TKI...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27493271/tert-promoter-mutation-predicts-radioiodine-refractory-in-distant-metastatic-differentiated-thyroid-cancer
#6
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin
: Telomerase Reverse Transcriptase (TERT) promoter mutation has been reported to be associated with aggressive characteristics in differentiated thyroid cancer (DTC). This study examined the status of TERT promoter mutation in distant metastatic DTC (DM-DTC), and evaluated the correlation between TERT mutation and radioactive iodine-131(RAI) uptake, as well as that between TERT mutation and therapy response. METHODS: TERT promoter and B-Raf proto-oncogene (BRAF) V600E mutation were retrospectively examined in primary tumors of 66 DM-DTC patients...
August 4, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27493262/grouping-of-metastatic-thyroid-carcinoma-by-molecular-imaging-features-to-allow-for-individualized-treatment-with-emphasis-on-the-tenis-syndrome
#7
Sandip Basu, Rahul Vithalrao Parghane
The process of radioiodine ((131)I) refractoriness, dedifferentiation, and development of thyroglobulin elevation and negative iodine scintigraphy (TENIS) syndrome in metastatic differentiated thyroid carcinoma (DTC) could be viewed as a disease continuum rather than a single event or an all-or-none phenomenon. In this report, the important role of molecular functional imaging in systematically exploring the disease biology and course of metastatic DTC is presented. Making this role the base, this report proposes a novel clinical classification for TENIS syndrome using molecular functional imaging...
September 2016: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/27398740/efficacy-of-lenvatinib-in-treating-thyroid-cancer
#8
Jolanta Krajewska, Aleksandra Kukulska, Barbara Jarzab
INTRODUCTION: Radioiodine [RAI]-resistant advanced and progressive differentiated thyroid cancer [DTC], although rare, constitutes a real challenge as its prognosis is poor and available therapeutic options, until now, have been limited. Discovery of a crucial role of distinct tyrosine kinases in DTC pathogenesis opened up new options in systemic treatment. Lenvatinib is an oral potent multi kinase inhibitor [MKI] of different growth factor receptors including VEGFR1/Flt-1, VEGFR2/KDR, VEGFR3, FGFR1,2,3,4, PDGFR-β as well as RET and KIT signaling networks...
August 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/27367142/targeted-therapies-in-thyroid-cancer-an-extensive-review-of-the-literature
#9
Athanasios Bikas, Shivangi Vachhani, Kirk Jensen, Vasyl Vasko, Kenneth D Burman
Introduction Patients with progressive, metastatic, RAI-refractory differentiated thyroid cancer (DTC), as well as patients with advanced medullary (MTC) and anaplastic thyroid cancer represent a cohort for which therapeutic options are limited. The recent discoveries in the molecular mechanisms implicated in TC have provided insight of the pathogenesis and progression of disease. In that respect, targeted therapies have emerged as a promising alternative for the treatment of those patients. Areas Covered Tyrosine Kinase Inhibitors (TKIs) have been studied extensively in TC: sorafenib and lenvatinib have been approved by the FDA for the treatment of metastatic, RAI-refractory DTC, while vandetanib and cabozantinib are FDA approved for use in advanced MTC...
July 1, 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/27313476/treatment-patterns-health-state-and-health-care-resource-utilization-of-patients-with-radioactive-iodine-refractory-differentiated-thyroid-cancer
#10
Andrew G Gianoukakis, Natalia M Flores, Corey L Pelletier, Anna Forsythe, Gregory R Wolfe, Matthew H Taylor
BACKGROUND: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. METHODS: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27306093/effects-and-role-of-multikinase-inhibitors-in-thyroid-cancer
#11
Rasmus Laursen, Markus Wehland, Sascha Kopp, Jessica Pietsch, Manfred Infanger, Jirka Grosse, Daniela Grimm
BACKGROUND: Thyroid cancer is the most common type of endocrine neoplasia. Differentiated thyroid carcinoma (DTC) represents 94% of all thyroid cancer types. Approximately 20% experience local recurrence and 10% distant metastasis. The recurrent DTC often becomes less differentiated, loses the iodine uptake capability and consequently loses the radioactive iodine treatment option. Under these circumstances survivability drops below 10% at 10 years. The treatment options for dedifferentiated thyroid cancers are extremely limited...
June 13, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27210070/tyrosine-kinase-inhibitors-to-treat-radioiodine-refracted-metastatic-or-recurred-and-progressive-differentiated-thyroid-carcinoma-review
#12
Yasuhiro Ito, Shinichi Suzuki, Ken-Ichi Ito, Tsuneo Imai, Takahiro Okamoto, Hiroya Kitano, Iwao Sugitani, Kiminori Sugino, Hidemitsu Tsutsui, Hisato Hara, Akira Yoshida, Kazuo Shimizu
Differentiated thyroid carcinoma (DTC) is generally indolent in nature and, even though it metastasizes to distant organs, the prognosis is normally excellent. In contrast, the overall survival (OS) of patients with radioactive iodine (RAI)-refractory and progressive metastases is dire, because no effective therapies have been available to control the metastatic lesions. However, recently, administration of tyrosine-kinase inhibitors (TKIs) has become a new line of therapy for RAI-refractory and progressive metastases...
July 30, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27207700/treatment-of-advanced-thyroid-cancer-with-targeted-therapies-ten-years-of-experience
#13
REVIEW
David Viola, Laura Valerio, Eleonora Molinaro, Laura Agate, Valeria Bottici, Agnese Biagini, Loredana Lorusso, Virginia Cappagli, Letizia Pieruzzi, Carlotta Giani, Elena Sabini, Paolo Passannati, Luciana Puleo, Antonio Matrone, Benedetta Pontillo-Contillo, Valentina Battaglia, Salvatore Mazzeo, Paolo Vitti, Rossella Elisei
Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such as papillary and follicular cancers, which have survival rates of approximately 95% at 40 years. However, 15-20% of cases became radioiodine refractory (RAI-R), and until now, no other treatments have been effective. The same problems are found in cases of poorly differentiated (PDTC) and anaplastic (ATC) thyroid cancers and in at least 30% of medullary thyroid cancer (MTC) cases, which are very aggressive and not sensitive to radioiodine...
April 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27139457/current-standards-in-treatment-of-radioiodine-refractory-thyroid-cancer
#14
REVIEW
Sujata Narayanan, A Dimitrios Colevas
Radioiodine refractory differentiated thyroid cancer (RAI-R DTC) is a challenging malignancy with limited prognosis and treatment options. Recently, clinical trials with targeted therapies have advanced the outlook of these patients, and inhibition of the vascular endothelial growth factor (VEGF) axis has led to the approval of small-molecule tyrosine kinase inhibitors (TKIs) for first-line treatment of radioiodine refractory disease. In addition to approved therapies (sorafenib and lenvatinib), other multi-targeted tyrosine kinase inhibitors that are commercially available have been recognized as viable treatment options for RAI-R DTC...
June 2016: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/27059853/-68-ga-dotatate-pet-mri-and-18-f-fdg-pet-ct-are-complementary-and-superior-to-diffusion-weighted-mr-imaging-for-radioactive-iodine-refractory-differentiated-thyroid-cancer
#15
Alexis Vrachimis, Lars Stegger, Christian Wenning, Benjamin Noto, Matthias Christian Burg, Julia Renate Konnert, Thomas Allkemper, Walter Heindel, Burkhard Riemann, Michael Schäfers, Matthias Weckesser
PURPOSE: The purpose of this study was to determine whether [(68)Ga]DOTATATE PET/MRI with diffusion-weighted imaging (DWI) can replace or complement [(18)F]FDG PET/CT in patients with radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC). METHODS: The study population comprised 12 patients with elevated thyroglobulin and a negative RAI scan after thyroidectomy and RAI remnant ablation who underwent both [(18)F]FDG PET/CT and [(68)Ga]DOTATATE PET/MRI within 8 weeks of each other...
September 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/26872102/time-course-and-predictors-of-structural-disease-progression-in-pulmonary-metastases-arising-from-follicular-cell-derived-thyroid-cancer
#16
Mona M Sabra, Ronald Ghossein, R Michael Tuttle
BACKGROUND: With the advent of molecular targeted therapy for the management of radioactive iodine (RAI) refractory, progressive metastatic thyroid cancer, it becomes important to define the time course and risk factors for structural disease progression in follicular cell-derived thyroid cancer (FCDTC) patients. This will help in defining the optimal time to start these therapies and better define their impact on structural disease progression. OBJECTIVES: This retrospective review of 199 consecutive patients with FCDTC presenting with lung metastasis examined the progression-free survival (PFS) in thyroid cancer patients with lung metastasis treated with surgery and RAI, and who had not received molecular targeted therapy or chemotherapy...
April 2016: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/26798849/pharmacological-and-clinical-profile-of-lenvatinib-e-7080-in-the-treatment-of-advanced-radioiodine-refractory-differentiated-thyroid-cancer
#17
REVIEW
M Hegazi, A Azadi, D Jain, R Redman, C A Perez
After the pathogenesis of thyroid carcinomas was better understood and the role of molecular alterations in RET, BRAF and RET/PTC rearrangement was revealed, several trials using multikinase inhibitors were developed during the last decade for the treatment of recurrent radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), achieving a remarkable success. Sorafenib became the first drug approved for this indication in more than two decades after a significant improvement in the progression-free survival was demonstrated...
December 2015: Drugs of Today
https://www.readbyqxmd.com/read/26678514/lenvatinib-role-in-thyroid-cancer-and-other-solid-tumors
#18
REVIEW
Maria E Cabanillas, Mouhammed Amir Habra
Despite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain poor. Treatment of advanced, progressive disease remains challenging, with limited treatment options. Small-molecule tyrosine kinase inhibitors, including vandetanib, cabozantinib, sorafenib, and lenvatinib, which are now FDA-approved for thyroid cancer, have shown clinical benefit in advanced thyroid cancer. Lenvatinib is approved for treatment of locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)...
January 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/26601805/spanish-consensus-for-the-management-of-patients-with-advanced-radioactive-iodine-refractory-differentiated-thyroid-cancer
#19
Garcilaso Riesco-Eizaguirre, Juan Carlos Galofré, Enrique Grande, Carles Zafón Llopis, Teresa Ramón y Cajal Asensio, Elena Navarro González, Paula Jiménez-Fonseca, Javier Santamaría Sandi, José Manuel Gómez Sáez, Jaume Capdevila
BACKGROUND: Approximately one third of the patients with differentiated thyroid cancer (DTC) who develop structurally-evident metastatic disease are refractory to radioactive iodine (RAI). Most deaths from thyroid cancer occur in these patients. The main objective of this consensus is to address the most controversial aspects of management of these patients. METHODS: On behalf of the Spanish Society of Endocrinology & Nutrition (SEEN) and the Spanish Group for Orphan and Infrequent Tumors (GETHI), the Spanish Task Force for Thyroid Cancer, consisting of endocrinologists and oncologists, reviewed the relevant literature and prepared a series of clinically relevant questions related to management of advanced RAI-refractory DTC...
April 2016: Endocrinología y Nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición
https://www.readbyqxmd.com/read/26532448/matching-adjusted-indirect-treatment-comparison-and-survival-extrapolation-in-radioiodine-refractory-differentiated-thyroid-cancer-rai-refractory-dtc-updated-analysis
#20
G Tremblay, C Pelletier, A Forsythe, U Majethia
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
54859
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"